BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38677742)

  • 1. A Machine Learning Model to Predict the Histology of Retroperitoneal Lymph Node Dissection Specimens.
    Nitta S; Kojima T; Gido M; Nakagawa S; Kakeya H; Kandori S; Kawahara T; Mathis BJ; Kawai K; Negoro H; Nishiyama H
    Anticancer Res; 2024 May; 44(5):2151-2157. PubMed ID: 38677742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.
    Baessler B; Nestler T; Pinto Dos Santos D; Paffenholz P; Zeuch V; Pfister D; Maintz D; Heidenreich A
    Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 5. Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor.
    Venishetty N; Taylor J; Xi Y; Howard JM; Ng YS; Wong D; Woldu SL; De Leon AD; Pedrosa I; Margulis V; Bagrodia A
    Clin Genitourin Cancer; 2024 Feb; 22(1):33-37. PubMed ID: 37468341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
    Williams SB; Kacker R; Steele GS; Richie JP
    Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
    Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
    Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
    Cary C; Pedrosa JA; Jacob J; Beck SD; Rice KR; Einhorn LH; Foster RS
    Cancer; 2015 Dec; 121(24):4369-75. PubMed ID: 26371446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection.
    Nestler T; Paffenholz P; Pfister D; Schoch J; Nini A; Hiester A; Albers P; Heidenreich A
    J Urol; 2024 Mar; 211(3):426-435. PubMed ID: 38085711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors.
    Lewin J; Dufort P; Halankar J; O'Malley M; Jewett MAS; Hamilton RJ; Gupta A; Lorenzo A; Traubici J; Nayan M; Leão R; Warde P; Chung P; Anson Cartwright L; Sweet J; Hansen AR; Metser U; Bedard PL
    JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
    Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
    J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
    Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF
    World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
    Djaladat H; Nichols C; Daneshmand S
    Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.
    Pietzak EJ; Assel M; Becerra MF; Tennenbaum D; Feldman DR; Bajorin DF; Motzer RJ; Bosl GJ; Carver BS; Sjoberg DD; Sheinfeld J
    Urology; 2018 Aug; 118():114-118. PubMed ID: 29704586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
    Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
    J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laparoscopic retroperitoneal lymph-node dissection in metastatic nonseminomatous germ-cell tumors.
    Nazzani S; Stagni S; Biasoni D; Catanzaro M; Macchi A; Tesone A; Torelli T; Darisi R; Lo Russo V; Colbacchini C; Lanocita R; Cascella T; Claps M; Giannatempo P; Zimatore M; Cattaneo L; Montanari E; Salvioni R; Nicolai N
    Eur J Surg Oncol; 2023 Jan; 49(1):257-262. PubMed ID: 36031470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
    Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
    Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors.
    Nguyen CT; Stephenson AJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):593-604, ix. PubMed ID: 21570611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.